Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
CD&R announced that Jim Lico, former President and CEO of Fortive, has been engaged as an Operating Advisor to CD&R funds effective April 28, 2026. Lico will support the Firm’s industrials team on sourcing investments and advising portfolio industrial businesses. He led Fortive from 2016–2025, helping grow market capitalization from $16B to $25B and delivering annual revenues above $6B. Lico serves on the boards of DuPont (DD) and PTC and brings nearly three decades of industrial and operational experience.
Danaher (NYSE: DHR) priced a €3.0 billion senior notes offering with four tranches due 2028, 2030, 2034 and 2038.
Net proceeds are estimated at approximately €2.98 billion, intended primarily to pay a portion of the cash consideration and certain costs for the acquisition of Masimo, with closing expected April 29, 2026.
Danaher (NYSE: DHR) reported Q1 2026 results: net earnings $1.0B and GAAP EPS $1.45. Revenues rose 3.5% to $6.0B; non-GAAP adjusted diluted EPS grew 9.5% to $2.06. Operating cash flow was $1.3B; non-GAAP free cash flow $1.1B. The company announced its intention to acquire Masimo and raised full‑year adjusted EPS guidance to $8.35–$8.55. Management expects 2026 non‑GAAP core revenue growth of 3%–6% and reiterated a Q2 low‑single digit revenue outlook.
Beckman Coulter Diagnostics (NYSE:DHR) received CE 2797 mark under IVDR on April 13, 2026 for the Access MeMed BV assay, enabling bacterial vs. viral differentiation in about 20 minutes on DxI 9000 and Access 2 analyzers across Europe.
The assay is supported by clinical studies and real‑world data showing up to 99% NPV and clinician impact in 82–87% of cases; independent modeling estimates up to €80 million in avoidable European healthcare costs through fewer unnecessary admissions and testing.
Danaher (NYSE: DHR) will host its First Quarter 2026 earnings conference call on Tuesday, April 21, 2026 at 8:00 a.m. ET.
The one-hour webcast will include discussion of financial results and outlook, a slide presentation, and a replay; earnings materials will be posted to the Investors section beginning at 6:00 a.m. ET on the call date.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable April 24, 2026, to shareholders of record on March 27, 2026.
The Board of Directors approved the dividend on February 24, 2026; the payment and record dates are specified for shareholder planning.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference in Boston on March 3, 2025 at 1:50 p.m. ET. The presentation will be webcast and accessible via Danaher's Investors site under Events & Presentations.
Masimo (Nasdaq: MASI) agreed to be acquired by Danaher (NYSE: DHR) for $180.00 per share in cash, representing total consideration of $9.9 billion. The boards of both companies unanimously approved the transaction.
Masimo will operate as a standalone business unit and brand within Danaher’s Diagnostics segment and is expected to close in the second half of 2026, subject to regulatory approvals. Masimo will report Q4 and full‑year 2025 results on Feb 26, 2026 but will not host an earnings call.
Danaher (NYSE: DHR) entered a definitive agreement to acquire Masimo (NASDAQ: MASI) for $180 per share in cash, implying an approximate $9.9 billion enterprise value including assumed debt and net of cash. The deal values Masimo at ~18x estimated 2027 EBITDA (15x including expected synergies).
Danaher expects Masimo to generate >$530 million EBITDA in 2027, deliver >$125 million annual cost synergies and >$50 million annual revenue synergies by year five, and be accretive to adjusted diluted EPS by $0.15–$0.20 in year one and ~ $0.70 in year five. Closing is anticipated in H2 2026, subject to regulatory clearances and Masimo shareholder approval.
Danaher (NYSE: DHR) reported Q4 2025 net earnings of $1.2 billion ($1.66 per diluted share) and full‑year net earnings of $3.6 billion ($5.03 per diluted share).
Q4 revenue rose 4.5% to $6.8 billion; FY2025 revenue was $24.6 billion (+3.0%). Non‑GAAP adjusted EPS grew ~4% Q4 and 4.5% FY. Operating cash flow was $2.1 billion in Q4 and $6.4 billion for FY; non‑GAAP free cash flow was $1.8 billion Q4 and $5.3 billion FY.
The company launched new products across bioprocessing, mass spectrometry, and diagnostics and initiated FY2026 guidance: core revenue +3–6% and adjusted EPS $8.35–8.50.